The pharmacokinetics and tolerance of acyclovir administered intravenously in single doses of 2.5, 5.0, 10.0, and 15.0 mg/kg were studied in 13 volunteers. The mean concentrations (± standard deviations) at the end of infusion as measured by radioimmunoassay were 4.52 ± 0.31, 8.28 ± 2.61, 14.6 ± 2.30, and 22.7 ± 10.4 pg/ml, respectively. Drug elimination during and after the infusion of acyclovir was well described by a two-compartment open model. The mean terminal plasma half-life for each of the groups was 2.85, 2.80, 3.30, and 2.38 h, respectively. Within 72 h after the start of the infusion, 70% of the adniinistered drug was recovered in the urine as unchanged acyclovir. The renal clearance of acyclovir accounted for about 77% of the total clearance and was about threefold greater than the creatinine clearance. This confirms that acyclovir is eliminated predominantly by the kidneys in patients with normal renal function and suggests that renal secretion and glomerular filtration may both be involved. The only adverse effect found by clinical and laboratory monitoring was irritation at the intravenous site after extravasation (in two cases), which resolved without significant sequelae.
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Acyclovir [9-(2-hydroxyethoxymethyl)guanine; acycloguanosine; Zovirax] is an acyclic nucleoside analog of guanosine which has a molecular weight of 225. Previous phase I studies have looked at the pharmacokinetics and tolerance of acyclovir at doses of up to 5 mg/kg given as a single intravenous infusion (4, 11) . In these single-dose studies, the half-life of acyclovir has been found to be about 3 h in patients with cancer who have normal renal function (4, 11) . When [14C]acyclovir was studied, almost all of the radioactivity was recovered in the urine as either unchanged acyclovir or its metabolite, 9-carboxymethoxymethylguanine (3a) . This metabolite accounted for approximately 8.5 to 14% of the total dose given.
Our study examines the pharmacokinetics and tolerance of acyclovir at doses of 2.5, 5, 10, and 15 mg/kg administered as a single 1-h infusion.
MATERIALS AND METHODS Patient selection. Thirteen patients (five males and eight females) with a mean age of 60 years (range, 23 to 76 years) were sequentially entered onto our study. Each of the patients had a malignancy, and most were followed at The Johns Hopkins Oncology Center Outpatient Clinics. Seven of the subjects had a hematological malignancy, four had breast carcinoma, one had lung carcinoma, and another had orbital rhabdomyosarcoma. The prognosis of each patient was such that the life expectancy was at least 6 months, and in many cases long-term prognosis was good. Several of the patients were receiving concurrent maintenance therapy. One subject had radiation therapy, one received prednisone, and one received a combination of prednisone and tamoxifen. The demographic data of these subjects are provided in Table 1 . Informed consent was obtained from all subjects before entry into the study. None of the patients had child-bearing potential, had either renal or hepatic dysfunction, had received pyrimidine or purine analogs or other drugs which affected purine metabolism or excretion, or had received any antiviral therapy in the week before the study.
Drug administration and dosage. Acyclovir was provided by the Burroughs-Wellcome Co. as the sterile, lyophilized sodium salt. Each 50-ml vial, containing 500 mg of acyclovir as the sodium salt, was reconstituted with 25 ml of sterile water for injection. The calculated dose for each patient was withdrawn, and enough Ringers lactate was added to bring the final volume to 60 ml. This was administered by constant intravenous infusion over 1 h (1 mlmin) via a peripheral vein. Subjects were divided into four groups: group A had three subjects who received 2.5 mg/kg; group B had three subjects. who received 5.0 mg/kg; group C had four subjects who received 10.0 mg/kg; and group D had three subjects who received 15 mg/kg.
CoLection of blood and urine specimens. Venous ANTIMICROB. AGENTS CHEMOTHER. Urine was collcted fractionally over a period of 72 h as follows: a baseline urine, 0 to 1 h (during the infusion), 1 to 5 h, S to 9 h, 9 to 13 h, 13 to 25 h, 25 to 48 h, and 48 to 72 h after the start of the infusion.
Monitoring toxicty. All patients had histories taken and physical and laboratory evaluations performed on admission to the Johns Hopkins Hospital Clinical Research Unit. Adverse clinical effects were sought daily for 4 days and then weekly for 3 weeks after the acyclovir infusion. Laboratory monitoring, including tests of hematologic, renal, and liver function, was followed daily during the 5-day hospitalization and then at weekly follow-up visits. Repeated examination of the acyclovir infusion site was done at least daily to monitor local adverse effects.
Acyclovir kle. Plasma and urine concentrations were determined by a sensitive and specific radioimmunoassay previously described (4, 10). The lower limit of detection by this assay is 0.05 ,uM (0.011 .g/ ml). All 
Initial estimates of A (micromolar), a, B (micromolar), and 0 were obtained by using the noniterative technique of Foss (6) . An iterative, nonlinear parameter estimation routine was then used to obtain a set of best-fit parameters based on the least-squares criteria. Alternate sets of inital parameters were also used with the iterative routine to insure that the final set ofparameters represented global minima. The parameter estimation routine was based on the NewtonRaphson technique as presented by Powell (9) and implemented on a Wang 2200 series desktop computer.
The second stage of the parameter search used both the infusion and postinfusion data. Its principal effect was to increase the reliability of the final estimates of the larger rate constants (associated with the more rapid processes). A best-fit set of the parameters in equation 1 was determined by using the nonlinear parameter estimation routine. Initial estimates of the additional parameters needed to start the iterative routine for the second stage were obtained from the results of the first stage by using equations 3 to 6, where V1 is the apparent volume of the central compartment, kl2 and k2l are the intercompartmental rate constants for transfer of drug from the central to the peripheral compartment and vice versa, respectively, and kIe is the apparent first-order rate constant of elimination. 
The area under the concentration-versus-time curve from time equals zero to infinity (AUCO') was determined by using equation 8 .
AUC 00= dose (8) The total body clearance (Clto0) of acyclovir was determined from the dose and the AUCo' by using equation 9. Cltot = keiV1 (9) The body surface area (BSA) in square meters of the patients was estimated using the relationship of Gehan and George (7) based on subject weight The weight (W) is in kilograms, the age (A) is in years, and the serum creatinine (Cr) is in milligrams per deciliter. Renal clearance for each collection interval up to 40 h was calculated by dividing the amount of acyclovir excreted unchanged during that interval by the area under the plasma concentration-versus-time curve calculated by the trapezoidal rule for the same interval. The acyclovir renal clearance of a subject (Clr) is the mean of the renal clearances calculated for the individual collection intervals, weighted by the fraction of the total urinary acyclovir that was recovered during that collection interval. 
RESULTS
Pharmacokinetic analysb. The declining plasma level after a 1-h infusion of acyclovir is well described by a two-compartment open model. This model was used to fit both the infusion and postinfusion data. The best-fit model curve describing the mean plasma concentration-versustime data (the mean of the concentrations at each time point) is shown for each of the four dosage groups in Fig. 1 . The plasma concentration-versus-time plots for the individual patients are similar to these typical curves at their respective dosage levels. Fig. 1 also provides the mean (± standard deviation) plasma concentrations of acyclovir during and after a 1-h infusion.
The kinetic parameters were computed for each individual patient by using the nonlinear parameter estimation routine. The group means and standard deviations for these data are presented in Table 2 .
The mean terminal (beta) half-lives for acyclovir were 2.9, 2.8, 3.3, and 2.4 h for the groups receiving 2.5, 5.0, 10.0, and 15.0 mg/kg, respectively. The longer mean half-life in the 10-mg/kg group may be attributed to patient 10 who, despite her serum creatinine of 1.2 mg/dl, had an estimated creatinine clearance of only 38 ml/ min. If her acyclovir half-life of 4.8 h is excluded, the mean half-life for that dosage level is reduced from 3.4 to 2.9 h.
The total clearance (Cltoj) of acyclovir was calculated for each dosage group. It was 239, 268, 321, and 394 ml/min per 1.73 m2 for those receiving 2.5, 5.0, 10.0, and 15.0 mg/kg, respectively. The total clearance was the greatest in the 15-mg/kg group; this group also had the shortest terminal half-life. However, this group had the highest mean creatinine clearance, and the average age of this group was about 25 years less than the other groups. This occurred strictly by chance, as the subjects were chosen in a sequential fashion. The volumes of distribution at steady state (Vd,,) for these same groups were 44.1, 43.1, 55.9, and 53.4 liters/1.73 m2, respectively. The volume of distribution in the central compartment (V1) was about 40%o of the Vd,, in each of the dosage groups.
Serum creatinines, the estimated creatinine clearances, total acyclovir clearances, and renal acyclovir clearances are given in Table 3 . The renal clearance was 77.4 + 3.1% of the total clearance of acyclovir and was about threefold greater than the estimated creatinine clearance. The amount of unchanged acyclovir eliminated in the urine was also measured. The urinary recovery data show that about 70%6 of acyclovir was excreted unchanged within 72 h. A previous study found that most of the unrecovered drug can be accounted for by the metabolism of acyclovir to carboyxmethoxymethylguanine (3a) . Since the Clr of acyclovir is about threefold greater than creatinine clearance, this suggests that renal elimination involves tubular secretion of acyclovir as well as glomerular filtration.
Acyclovir is a very potent and selective antiherpesvirus agent, and certain herpesviruses are extremely susceptible to acyclovir. The 50% inhibitory doses are about 0.03, 0.36, and 0.84 ,ug/ml against herpes simplex virus types 1 and 2 and varicella-zoster virus, respectively (3). Most strains of cytomegalovirus appear to be relatively resistant (50% inhibitory dose, >45 ,ug/ml) (3) . In vitro, acyclovir has a high therapeutic index, inhibiting mammalian cell growth only at very high concentrations (about 67.5 ,ug/ml) (2, 5) . Even then the cells remain viable and growth recurs when the acyclovir is removed (2) . In humans, acyclovir appears to be relatively safe and well tolerated. None of our patients or those in other single-dose studies (1, 3a, 4, 11) developed any significant toxicity. Only when the drug extravasated were there any adverse reactions, and these were local irritations which resolved without long-lasting effects. The local reaction may be secondary to the pH of the infusing solution (pH >9) rather than to the direct effect of the drug.
The results of this study, at higher drug dosages than in previous studies, show that it is possible to achieve for at least 7 h plasma concentrations substantially higher than the 50% inhibitory doses of the susceptible herpesviruses in the absence of significant acute toxicities.
